Lingshan Gou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lingshan Gou has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Maosheng Gu
Center for Genetic Medicine, Xuzhou Maternity and Child Health Care Hospital Affiliated to Xuzhou Medical University
4 shared publications Chuanxia Wang
Center for Genetic Medicine, Xuzhou Maternity and Child Health Care Hospital Affiliated to Xuzhou Medical University, Xuzhou, China
2 shared publicationsFeng Suo
Center for Genetic Medicine, Xuzhou Maternity and Child Health Care Hospital Affiliated to Xuzhou Medical University, Xuzhou, China
2 shared publications- Feng Suo
Center for Genetic Medicine, Xuzhou Maternity and Child Health Care Hospital Affiliated to Xuzhou Medical University
2 shared publications Man Zhang
Department of Technology, Zhejiang Biosan Biochemical Technologies Co., Ltd, Hangzhou, China
2 shared publicationsNa Wang
School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China
2 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1)
Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with maternal serum bile acid profiles
- 18 November 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1)
Open AccessAssociation of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with maternal serum bile acid profiles
- Open Access
- 19 June 2026
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 13, 1896846
Editorial: Epigenetic and genetic mechanisms underlying cardiovascular diseases and neurodevelopmental disorders, volume II
Tada et al., 2021;Shi et al., 2022). Dissecting these etiological mechanisms is pivotal to advancing targeted therapeutic strategies for clinical management. This Research Topic presents ten articles including eight original research and two review articles, that collectively explore the genetics and epigenetic bases, as well as therapeutic targets, underlying these conditions. Epigenetic regulation, encompassing mechanisms such as DNA methylation, histone modification, and non-coding RNAs, serves as a critical intermediary, enabling environmental factors to influence gene expression without altering the DNA sequence itself, and plays a pivotal role in the onset and progression of CVD (Hartiala et al., 2021;Shi et al., 2022;Pang et al., 2024;Gao et al., 2026) Kawasaki disease (KD), an acute vasculitis primarily affecting young children, presents a significant challenge in pediatric healthcare. Nonetheless, the cellular heterogeneity and underlying pathogenic mechanisms of this disease remain inadequately understood (Vaňková et al., 2023;Burns, 2024). Their longitudinal study revealed phase-dependent changes in platelet parameters and identified the rs8090438 variant in the MBP gene as a potential genetic factor associated with reduced aspirin responsiveness.Pulmonary arterial hypertension and chronic heart failure present substantial challenges within the domain of CVD (Chizinga et al., 2018;Heidenreich et al., 2022;Wu et al., 2025;Liu et al., 2026). In this Research Topic, one original Abnormalities in the genetic architecture of CVD have been extensivelydocumented; however, their genetic etiologies remain largely elusive (Heimlich et al., 2022;Yu et al., 2023;Qiao et al., 2025). Addressing this critical knowledge gap, two
- 19 June 2026
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 13, 1896846
Open AccessEditorial: Epigenetic and genetic mechanisms underlying cardiovascular diseases and neurodevelopmental disorders, volume II
Tada et al., 2021;Shi et al., 2022). Dissecting these etiological mechanisms is pivotal to advancing targeted therapeutic strategies for clinical management. This Research Topic presents ten articles including eight original research and two review articles, that collectively explore the genetics and epigenetic bases, as well as therapeutic targets, underlying these conditions. Epigenetic regulation, encompassing mechanisms such as DNA methylation, histone modification, and non-coding RNAs, serves as a critical intermediary, enabling environmental factors to influence gene expression without altering the DNA sequence itself, and plays a pivotal role in the onset and progression of CVD (Hartiala et al., 2021;Shi et al., 2022;Pang et al., 2024;Gao et al., 2026) Kawasaki disease (KD), an acute vasculitis primarily affecting young children, presents a significant challenge in pediatric healthcare. Nonetheless, the cellular heterogeneity and underlying pathogenic mechanisms of this disease remain inadequately understood (Vaňková et al., 2023;Burns, 2024). Their longitudinal study revealed phase-dependent changes in platelet parameters and identified the rs8090438 variant in the MBP gene as a potential genetic factor associated with reduced aspirin responsiveness.Pulmonary arterial hypertension and chronic heart failure present substantial challenges within the domain of CVD (Chizinga et al., 2018;Heidenreich et al., 2022;Wu et al., 2025;Liu et al., 2026). In this Research Topic, one original Abnormalities in the genetic architecture of CVD have been extensivelydocumented; however, their genetic etiologies remain largely elusive (Heimlich et al., 2022;Yu et al., 2023;Qiao et al., 2025). Addressing this critical knowledge gap, two
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Endocrinology
- Vol. 2026 (1)
Glycoursodeoxycholic Acid and Insulin Resistance in Women With Normoandrogenic Polyendocrine Metabolic Ovarian Syndrome Undergoing In Vitro Fertilization
Aim: To characterize paired serum and follicular fluid (FF) bile acids in normoandrogenic polyendocrine metabolic ovarian syndrome (NA‐PMOS) and investigate associations of glycoursodeoxycholic acid (GUDCA) with endocrine‐metabolic indices and in vitro fertilization (IVF) outcomes. Methods: This retrospective case–control study included 20 women with NA‐PMOS and 20 age‐comparable controls without PMOS undergoing IVF. Fifteen bile acids were measured in serum and FF. Analyses assessed group differences, metabolic and IVF associations, and discrimination between diagnostic groups. Results: Compared with controls without PMOS, women with NA‐PMOS had higher fasting insulin, triglycerides, and triglyceride–glucose (TyG) index and a lower high‐quality embryo rate. GUDCA was lower in NA‐PMOS in FF (137.01 vs. 332.60 nmol/L; p = 0.0004768; q = 0.007152) and serum (31.59 vs. 71.85 nmol/L; p = 0.03022; q = 0.2704). Apparent areas under the curve (AUCs) were 0.849 for FF, 0.713 for serum, and 0.871 for their combination. Serum GUDCA correlated inversely with TyG ( ρ = −0.582, p = 0.0028); the association persisted after adjustment for age, BMI, and diagnostic group ( β = −0.348, p = 0.0415). Within NA‐PMOS, serum GUDCA correlated inversely with fasting insulin and homeostasis model assessment of insulin resistance (HOMA‐IR). In the pooled cohort, FF GUDCA correlated inversely with baseline anti‐Müllerian hormone, total testosterone, and oocyte counts. GUDCA in neither matrix was significantly associated with high‐quality embryo rate. Conclusions: Lower GUDCA in serum and FF characterizes this exploratory IVF‐based NA‐PMOS sample, with stronger between‐group evidence in FF. Serum GUDCA was associated with metabolic indices, while FF GUDCA was associated with ovarian characteristics and response. No significant association with high‐quality embryo rate was observed. These findings warrant prospective validation.
- 1 January 2026
- Published by Wiley in International Journal of Endocrinology
- Vol. 2026 (1)
Open AccessGlycoursodeoxycholic Acid and Insulin Resistance in Women With Normoandrogenic Polyendocrine Metabolic Ovarian Syndrome Undergoing In Vitro Fertilization
Aim: To characterize paired serum and follicular fluid (FF) bile acids in normoandrogenic polyendocrine metabolic ovarian syndrome (NA‐PMOS) and investigate associations of glycoursodeoxycholic acid (GUDCA) with endocrine‐metabolic indices and in vitro fertilization (IVF) outcomes. Methods: This retrospective case–control study included 20 women with NA‐PMOS and 20 age‐comparable controls without PMOS undergoing IVF. Fifteen bile acids were measured in serum and FF. Analyses assessed group differences, metabolic and IVF associations, and discrimination between diagnostic groups. Results: Compared with controls without PMOS, women with NA‐PMOS had higher fasting insulin, triglycerides, and triglyceride–glucose (TyG) index and a lower high‐quality embryo rate. GUDCA was lower in NA‐PMOS in FF (137.01 vs. 332.60 nmol/L; p = 0.0004768; q = 0.007152) and serum (31.59 vs. 71.85 nmol/L; p = 0.03022; q = 0.2704). Apparent areas under the curve (AUCs) were 0.849 for FF, 0.713 for serum, and 0.871 for their combination. Serum GUDCA correlated inversely with TyG ( ρ = −0.582, p = 0.0028); the association persisted after adjustment for age, BMI, and diagnostic group ( β = −0.348, p = 0.0415). Within NA‐PMOS, serum GUDCA correlated inversely with fasting insulin and homeostasis model assessment of insulin resistance (HOMA‐IR). In the pooled cohort, FF GUDCA correlated inversely with baseline anti‐Müllerian hormone, total testosterone, and oocyte counts. GUDCA in neither matrix was significantly associated with high‐quality embryo rate. Conclusions: Lower GUDCA in serum and FF characterizes this exploratory IVF‐based NA‐PMOS sample, with stronger between‐group evidence in FF. Serum GUDCA was associated with metabolic indices, while FF GUDCA was associated with ovarian characteristics and response. No significant association with high‐quality embryo rate was observed. These findings warrant prospective validation.
- 17 March 2025
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 417 (13) , 2889-2902
Metabolite biomarkers of screening neonatal congenital hypothyroidism based on dried blood spot metabolomics
Congenital hypothyroidism (CH) can be detected early during thyroid-stimulating hormone (TSH) screening based on dried blood spot (DBS) samples. However, it falls short in differentiating between neonates with elevated TSH levels and those with CH, which leads to many neonates undergoing secondary diagnosis through venous blood sampling. Metabolomics was used to analyze metabolic alterations in neonates with CH, and identify DBS-based metabolite biomarkers for CH screening to reduce secondary diagnosis. Based on non-targeted metabolomics, the metabolic alterations in neonates with CH were analyzed in a discovery set and novel biomarkers were identified. The results of the discovery set revealed that the metabolic alterations in neonates with CH were primarily in amino acid and lipid metabolism, and identified novel metabolite biomarkers were thyroxine, 2-piperidinone, and PC (14:0/20:4). Then, these biomarkers were validated in a validation set, and the screening performance was still satisfactory. A rapid 3.5-min targeted method for three potential biomarkers was further developed and used to analyze a confirmation set. Analysis of the confirmation set re-validated the reliability of the biomarkers, and a biomarker combinational model equation and an appropriate cutoff value were defined. Each set of DBS samples included neonates with health, hyperthyrotropinemia, and CH. The novel metabolite biomarkers from DBS samples demonstrate significant potential for CH screening in neonates, effectively reducing the requirement associated with secondary diagnosis of mis-screened neonates. Graphical Abstract
- 17 March 2025
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 417 (13) , 2889-2902
Metabolite biomarkers of screening neonatal congenital hypothyroidism based on dried blood spot metabolomics
Congenital hypothyroidism (CH) can be detected early during thyroid-stimulating hormone (TSH) screening based on dried blood spot (DBS) samples. However, it falls short in differentiating between neonates with elevated TSH levels and those with CH, which leads to many neonates undergoing secondary diagnosis through venous blood sampling. Metabolomics was used to analyze metabolic alterations in neonates with CH, and identify DBS-based metabolite biomarkers for CH screening to reduce secondary diagnosis. Based on non-targeted metabolomics, the metabolic alterations in neonates with CH were analyzed in a discovery set and novel biomarkers were identified. The results of the discovery set revealed that the metabolic alterations in neonates with CH were primarily in amino acid and lipid metabolism, and identified novel metabolite biomarkers were thyroxine, 2-piperidinone, and PC (14:0/20:4). Then, these biomarkers were validated in a validation set, and the screening performance was still satisfactory. A rapid 3.5-min targeted method for three potential biomarkers was further developed and used to analyze a confirmation set. Analysis of the confirmation set re-validated the reliability of the biomarkers, and a biomarker combinational model equation and an appropriate cutoff value were defined. Each set of DBS samples included neonates with health, hyperthyrotropinemia, and CH. The novel metabolite biomarkers from DBS samples demonstrate significant potential for CH screening in neonates, effectively reducing the requirement associated with secondary diagnosis of mis-screened neonates. Graphical Abstract
- Top Cited Papers
- 7 February 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 408, 111418
Lactate-triggered histone lactylation contributes to podocyte epithelial-mesenchymal transition in diabetic nephropathy in mice
- 7 February 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 408, 111418
Top Cited PapersLactate-triggered histone lactylation contributes to podocyte epithelial-mesenchymal transition in diabetic nephropathy in mice
- Open Access
- 3 April 2024
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 15, 1401354
Editorial: Epigenetic and genetic mechanisms underlying cardiovascular diseases and neurodevelopmental disorders
Epigenetic and genetic mechanisms underlying cardiovascular diseases and neurodevelopmental disorders Cardiovascular diseases (CVD) and neurodevelopmental disorders (NDD) represent significant health challenges, posing severe threats to human health and quality of life. Emerging as the foremost cause of mortality and disability globally, CVD is intricately linked with a variety of factors such as chronic inflammation and genetic predispositions (Dzau and Hodgkinson, 2024). Similarly, NDD, characterized by deficits in cognitive functions, social interactions, and learning capabilities (Olson et al., 2024), demands deeper understanding of their genetic and epigenetic underpinnings. The complexities of these diseases stem from a multifaceted etiology involving DNA variants, epigenetic modifications, and environmental influences, a narrative supported by research from Srour and Shevell (2014), Homberg et al. (2016), and Hartiala et al. (2021). Chronic inflammation plays a pivotal role in CVD, such as acute myocardial infarction (AMI) and coronary artery disease (CAD) (Liu C. et al., 2022; Lopez-Candales et al., 2017). Macrophage migration inhibitory factor (MIF) is an important pro-inflammatory cytokine implicated in the pathogenesis of CVD (Zernecke et al., 2008). MIF gene, located at 22q11.2, features polymorphisms such as-173 G/C polymorphism (rs755622), and-974 CATT tetranucleotide repeat (rs5844572), which may influence gene transcription and inflammatory processes. Fouda et al. conducted a meta-analysis of the MIF-173G/C variant's impact on CVD risk in 9,047 participants, revealing its association with increased CVD risk in specific populations, highlighting the genetic underpinnings of inflammation in CVD. AMI is a life-threatening disease involving thrombosis, fibrinolysis, inflammation, and lipid metabolism. Jeon et al. identified six early-onset AMI-associated variants, notably rs12639023 as a prognostic marker for cardiac mortality. This genetic perspective is crucial for understanding AMI's complex pathogenesis. Despite extensive research, the
- 3 April 2024
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 15, 1401354
Open AccessEditorial: Epigenetic and genetic mechanisms underlying cardiovascular diseases and neurodevelopmental disorders
Epigenetic and genetic mechanisms underlying cardiovascular diseases and neurodevelopmental disorders Cardiovascular diseases (CVD) and neurodevelopmental disorders (NDD) represent significant health challenges, posing severe threats to human health and quality of life. Emerging as the foremost cause of mortality and disability globally, CVD is intricately linked with a variety of factors such as chronic inflammation and genetic predispositions (Dzau and Hodgkinson, 2024). Similarly, NDD, characterized by deficits in cognitive functions, social interactions, and learning capabilities (Olson et al., 2024), demands deeper understanding of their genetic and epigenetic underpinnings. The complexities of these diseases stem from a multifaceted etiology involving DNA variants, epigenetic modifications, and environmental influences, a narrative supported by research from Srour and Shevell (2014), Homberg et al. (2016), and Hartiala et al. (2021). Chronic inflammation plays a pivotal role in CVD, such as acute myocardial infarction (AMI) and coronary artery disease (CAD) (Liu C. et al., 2022; Lopez-Candales et al., 2017). Macrophage migration inhibitory factor (MIF) is an important pro-inflammatory cytokine implicated in the pathogenesis of CVD (Zernecke et al., 2008). MIF gene, located at 22q11.2, features polymorphisms such as-173 G/C polymorphism (rs755622), and-974 CATT tetranucleotide repeat (rs5844572), which may influence gene transcription and inflammatory processes. Fouda et al. conducted a meta-analysis of the MIF-173G/C variant's impact on CVD risk in 9,047 participants, revealing its association with increased CVD risk in specific populations, highlighting the genetic underpinnings of inflammation in CVD. AMI is a life-threatening disease involving thrombosis, fibrinolysis, inflammation, and lipid metabolism. Jeon et al. identified six early-onset AMI-associated variants, notably rs12639023 as a prognostic marker for cardiac mortality. This genetic perspective is crucial for understanding AMI's complex pathogenesis. Despite extensive research, the
- Open Access
- 6 December 2023
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 43 (2) , 2288226
Discordant performances of non-invasive prenatal testing for foetal trisomy 21 screening in subgroups of pregnancies
Non-invasive prenatal testing (NIPT) has been widely adopted as an approach for foetal aneuploidy screening. This study was to evaluate the performance of NIPT for foetal T21 detection in subgroups of pregnancies and the correlation between Z-score and discordant positive predictive values (PPVs). We retrospectively reviewed the NIPT results among 22361 pregnancies undergoing combined second-trimester screening (cSTS) previously. Sixty-four cases with positive NIPT results for foetal T21 were validated by invasive prenatal diagnosis. In pregnancies with cSTS-T21 low-, intermediate-, and high-risk, the PPVs at NIPT were 14.3%, 64.3%, and 86.4%, respectively. Mean Z-scores of positive NIPT cases with cSTS-T21 high- and intermediate-risk were comparable, while were higher than that of cases with pre-test low-risk. Furthermore, PPVs for positive NIPT cases at 3 < Z < 5, 5 ≤ Z < 9, and Z ≥ 9 were 16.7%, 63.2%, and 100.0%, respectively. This study suggested that Z-score value of positive cases might be associated with discordant PPVs for T21 screening in subgroups of pregnancies.
- 6 December 2023
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 43 (2) , 2288226
Open AccessDiscordant performances of non-invasive prenatal testing for foetal trisomy 21 screening in subgroups of pregnancies
Non-invasive prenatal testing (NIPT) has been widely adopted as an approach for foetal aneuploidy screening. This study was to evaluate the performance of NIPT for foetal T21 detection in subgroups of pregnancies and the correlation between Z-score and discordant positive predictive values (PPVs). We retrospectively reviewed the NIPT results among 22361 pregnancies undergoing combined second-trimester screening (cSTS) previously. Sixty-four cases with positive NIPT results for foetal T21 were validated by invasive prenatal diagnosis. In pregnancies with cSTS-T21 low-, intermediate-, and high-risk, the PPVs at NIPT were 14.3%, 64.3%, and 86.4%, respectively. Mean Z-scores of positive NIPT cases with cSTS-T21 high- and intermediate-risk were comparable, while were higher than that of cases with pre-test low-risk. Furthermore, PPVs for positive NIPT cases at 3 < Z < 5, 5 ≤ Z < 9, and Z ≥ 9 were 16.7%, 63.2%, and 100.0%, respectively. This study suggested that Z-score value of positive cases might be associated with discordant PPVs for T21 screening in subgroups of pregnancies.
- 18 November 2021
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 395 (1) , 77-85
Lack of miRNA-17 family mediates high glucose-induced PAR-1 upregulation in glomerular mesangial cells
Upregulation of thrombin receptor protease-activated receptor 1 (PAR-1) is verified to contribute to chronic kidney diseases, including diabetic nephropathy; however, the mechanisms are still unclear. In this study, we investigated the effect of PAR-1 on high glucose-induced proliferation of human glomerular mesangial cells (HMCs), and explored the mechanism of PAR-1 upregulation from alteration of microRNAs. We found that high glucose stimulated proliferation of the mesangial cells whereas PAR-1 inhibition with vorapaxar attenuated the cell proliferation. Moreover, high glucose upregulated PAR-1 in mRNA level and protein expression while did not affect the enzymatic activity of thrombin in HMCs after 48 h culture. Then high glucose induced PAR-1 elevation was likely due to the alteration of the transcription or post-transcriptional processing. It was found that miR-17 family members including miR-17-5p, -20a-5p, and -93-5p were significantly decreased among the eight detected microRNAs only in high glucose-cultured HMCs, but miR-129-5p, miR-181a-5p, and miR-181b-5p were markedly downregulated in both high glucose-cultured HMCs and equivalent osmotic press control compared with normal glucose culture. So miR-20a was selected to confirm the role of miR-17 family on PAR-1 upregulation, finding that miR-20a-5p overexpression reversed the upregulation of PAR-1 in mRNA and protein levels induced by high glucose in HMCs. In summary, our finding indicated that PAR-1 upregulation mediated proliferation of glomerular mesangial cells induced by high glucose, and deficiency of miR-17 family resulted in PAR-1 upregulation.
- 18 November 2021
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 395 (1) , 77-85
Lack of miRNA-17 family mediates high glucose-induced PAR-1 upregulation in glomerular mesangial cells
Upregulation of thrombin receptor protease-activated receptor 1 (PAR-1) is verified to contribute to chronic kidney diseases, including diabetic nephropathy; however, the mechanisms are still unclear. In this study, we investigated the effect of PAR-1 on high glucose-induced proliferation of human glomerular mesangial cells (HMCs), and explored the mechanism of PAR-1 upregulation from alteration of microRNAs. We found that high glucose stimulated proliferation of the mesangial cells whereas PAR-1 inhibition with vorapaxar attenuated the cell proliferation. Moreover, high glucose upregulated PAR-1 in mRNA level and protein expression while did not affect the enzymatic activity of thrombin in HMCs after 48 h culture. Then high glucose induced PAR-1 elevation was likely due to the alteration of the transcription or post-transcriptional processing. It was found that miR-17 family members including miR-17-5p, -20a-5p, and -93-5p were significantly decreased among the eight detected microRNAs only in high glucose-cultured HMCs, but miR-129-5p, miR-181a-5p, and miR-181b-5p were markedly downregulated in both high glucose-cultured HMCs and equivalent osmotic press control compared with normal glucose culture. So miR-20a was selected to confirm the role of miR-17 family on PAR-1 upregulation, finding that miR-20a-5p overexpression reversed the upregulation of PAR-1 in mRNA and protein levels induced by high glucose in HMCs. In summary, our finding indicated that PAR-1 upregulation mediated proliferation of glomerular mesangial cells induced by high glucose, and deficiency of miR-17 family resulted in PAR-1 upregulation.
- 17 August 2021
- Published by Springer Nature in Current Medical Science
- Vol. 41 (4) , 746-756
The Potential Immunomodulatory Properties of Levornidazole Contribute to Improvement in Experimental Ulcerative Colitis
The use of an antibiotic with immunomodulatory properties could be fascinating in treating multifactorial inflammatory conditions such as ulcerative colitis (UC). We report our investigations into the immunomodulatory properties of levornidazole, the S-enantiomer of ornidazole, which displayed a tremendous therapeutic potential in UC induced by dextran sodium sulfate (DSS). Levornidazole administration to DSS-colitic mice attenuated the intestinal inflammatory process, with an efficacy better than that shown by 5-amino salicylic acid. This was evidenced by decreased disease activity index, ameliorated macroscopic and microscopic colon damages, and reduced expression of inflammatory cytokines. Additionally, levornidazole displayed anti-inflammatory activity through Caveolin-1-dependent reducing IL-1β and IL-18 secretion by macrophages contributing to its improvement of the intestinal inflammation, as confirmed in vitro and in vivo. In conclusion, these results pointed out that the immunomodulatory effects of levornidazole played a vital role in ameliorating the intestinal inflammatory process, which would be crucial for the translation of its use into clinical settings.
- 17 August 2021
- Published by Springer Nature in Current Medical Science
- Vol. 41 (4) , 746-756
The Potential Immunomodulatory Properties of Levornidazole Contribute to Improvement in Experimental Ulcerative Colitis
The use of an antibiotic with immunomodulatory properties could be fascinating in treating multifactorial inflammatory conditions such as ulcerative colitis (UC). We report our investigations into the immunomodulatory properties of levornidazole, the S-enantiomer of ornidazole, which displayed a tremendous therapeutic potential in UC induced by dextran sodium sulfate (DSS). Levornidazole administration to DSS-colitic mice attenuated the intestinal inflammatory process, with an efficacy better than that shown by 5-amino salicylic acid. This was evidenced by decreased disease activity index, ameliorated macroscopic and microscopic colon damages, and reduced expression of inflammatory cytokines. Additionally, levornidazole displayed anti-inflammatory activity through Caveolin-1-dependent reducing IL-1β and IL-18 secretion by macrophages contributing to its improvement of the intestinal inflammation, as confirmed in vitro and in vivo. In conclusion, these results pointed out that the immunomodulatory effects of levornidazole played a vital role in ameliorating the intestinal inflammatory process, which would be crucial for the translation of its use into clinical settings.
- Open Access
- 5 May 2021
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 9 (6) , e1687
Clinical value for the detection of fetal chromosomal deletions/duplications by noninvasive prenatal testing in clinical practice
Objective: This study was to report the experiences on the clinical value of noninvasive prenatal testing (NIPT) for the screening of fetal chromosomal deletions/duplications.Methods: We performed a retrospective analysis of a cohort of 20,439 pregnancies undergoing NIPT from March 2017 to September 2020 at a single center. Patients with positive NIPT results for fetal chromosomal deletions or duplications had options of invasive diagnostic testing or no further testing. The data were complied from all cases with positive NIPT results for chromosomal deletions/duplications. The positive predictive value (PPV) was calculated from tabulated data.Results: In this cohort, positive NIPT results for fetal chromosomal deletions/duplications were found in 60 pregnant women. Of the positive samples, further invasive testing was performed in 39 cases, in which 9 cases were found to be true positive. The overall PPV for chromosomal deletions/duplications was 23.1%. In addition, fetal structural anomaly was found by ultrasound examination in three cases, in which the chromosomal deletions/duplications of three cases were not verified. Moreover, an unexpected pathogenic 8p23.3 deletion was identified by invasive testing in 1 fetus with a false positive NIPT screen for 3q27.3q29 duplication.Conclusions: In summary, positive NIPT results of chromosomal deletions/duplications were not uncommon in clinical practice, whereas the PPV for the testing was low. Hence, potential risks and high percentage of false positives for these abnormal NIPT results might be informed to pregnant women before the choice made of invasive testing.
- 5 May 2021
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 9 (6) , e1687
Open AccessClinical value for the detection of fetal chromosomal deletions/duplications by noninvasive prenatal testing in clinical practice
Objective: This study was to report the experiences on the clinical value of noninvasive prenatal testing (NIPT) for the screening of fetal chromosomal deletions/duplications.Methods: We performed a retrospective analysis of a cohort of 20,439 pregnancies undergoing NIPT from March 2017 to September 2020 at a single center. Patients with positive NIPT results for fetal chromosomal deletions or duplications had options of invasive diagnostic testing or no further testing. The data were complied from all cases with positive NIPT results for chromosomal deletions/duplications. The positive predictive value (PPV) was calculated from tabulated data.Results: In this cohort, positive NIPT results for fetal chromosomal deletions/duplications were found in 60 pregnant women. Of the positive samples, further invasive testing was performed in 39 cases, in which 9 cases were found to be true positive. The overall PPV for chromosomal deletions/duplications was 23.1%. In addition, fetal structural anomaly was found by ultrasound examination in three cases, in which the chromosomal deletions/duplications of three cases were not verified. Moreover, an unexpected pathogenic 8p23.3 deletion was identified by invasive testing in 1 fetus with a false positive NIPT screen for 3q27.3q29 duplication.Conclusions: In summary, positive NIPT results of chromosomal deletions/duplications were not uncommon in clinical practice, whereas the PPV for the testing was low. Hence, potential risks and high percentage of false positives for these abnormal NIPT results might be informed to pregnant women before the choice made of invasive testing.